Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery
© 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society..
OBJECTIVE: This retrospective cohort study aimed to assess the effectiveness of semaglutide 2.4 mg in patients with severe obesity (BMI ≥ 40 kg/m2 ) who had previously undergone bariatric surgery (BS) but failed to achieve satisfactory weight loss or experienced weight regain compared with patients without a history of BS with similar BMI.
METHODS: The authors analyzed data from 129 patients with a BMI ≥ 40 kg/m2 , including 39 with (BS+) and 90 without (BS-) a history of BS. The patients received semaglutide treatment for 24 weeks starting at 0.25 mg/wk and gradually increasing to reach a final dose of 2.4 mg/wk. The treatment outcomes were assessed based on the percentage of weight loss, changes in BMI, and waist circumference.
RESULTS: Semaglutide treatment resulted in significant 9.1% weight loss in the BS+ group, with no significant difference in weight loss between the BS+ and BS- groups.
CONCLUSIONS: This study is the first, to the authors' knowledge, to compare the effectiveness of semaglutide treatment in patients with versus those without a history of BS, providing valuable evidence of its efficacy. By focusing on individuals with severe obesity (BMI > 40 kg/m2 and associated comorbidities), it fills a gap in the current literature and highlights the potential of semaglutide 2.4 mg as a treatment option for this specific population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Obesity (Silver Spring, Md.) - 32(2023), 1 vom: 01. Jan., Seite 50-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bonnet, Jean-Baptiste [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/oby.23922 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364189959 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364189959 | ||
| 003 | DE-627 | ||
| 005 | 20231227140921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/oby.23922 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM364189959 | ||
| 035 | |a (NLM)37927153 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bonnet, Jean-Baptiste |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society. | ||
| 520 | |a OBJECTIVE: This retrospective cohort study aimed to assess the effectiveness of semaglutide 2.4 mg in patients with severe obesity (BMI ≥ 40 kg/m2 ) who had previously undergone bariatric surgery (BS) but failed to achieve satisfactory weight loss or experienced weight regain compared with patients without a history of BS with similar BMI | ||
| 520 | |a METHODS: The authors analyzed data from 129 patients with a BMI ≥ 40 kg/m2 , including 39 with (BS+) and 90 without (BS-) a history of BS. The patients received semaglutide treatment for 24 weeks starting at 0.25 mg/wk and gradually increasing to reach a final dose of 2.4 mg/wk. The treatment outcomes were assessed based on the percentage of weight loss, changes in BMI, and waist circumference | ||
| 520 | |a RESULTS: Semaglutide treatment resulted in significant 9.1% weight loss in the BS+ group, with no significant difference in weight loss between the BS+ and BS- groups | ||
| 520 | |a CONCLUSIONS: This study is the first, to the authors' knowledge, to compare the effectiveness of semaglutide treatment in patients with versus those without a history of BS, providing valuable evidence of its efficacy. By focusing on individuals with severe obesity (BMI > 40 kg/m2 and associated comorbidities), it fills a gap in the current literature and highlights the potential of semaglutide 2.4 mg as a treatment option for this specific population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a semaglutide |2 NLM | |
| 650 | 7 | |a 53AXN4NNHX |2 NLM | |
| 700 | 1 | |a Tournayre, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Anitcheou, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Faivre, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Boegner, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Jalek, Abdulkader |e verfasserin |4 aut | |
| 700 | 1 | |a Jullien, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Attalin, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Myzia, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Marty, Lucile |e verfasserin |4 aut | |
| 700 | 1 | |a Kemba, Youadigue |e verfasserin |4 aut | |
| 700 | 1 | |a Nocca, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sultan, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Avignon, Antoine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obesity (Silver Spring, Md.) |d 2006 |g 32(2023), 1 vom: 01. Jan., Seite 50-58 |w (DE-627)NLM160857384 |x 1930-739X |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:50-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/oby.23922 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 1 |b 01 |c 01 |h 50-58 | ||